featured
Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Lancet Oncol 2024 Nov 01;25(11)1424-1439, M Oliveira, D Pominchuk, Z Nowecki, E Hamilton, Y Kulyaba, T Andabekov, Y Hotko, T Melkadze, G Nemsadze, P Neven, V Vladimirov, C Zamagni, H Denys, F Forget, Z Horvath, A Nesterova, M Ajimi, B Kirova, T Klinowska, JPO Lindemann, D Lissa, A Mathewson, CJ Morrow, Z Traugottova, R van Zyl, E ArkaniaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.